Article Information
History
- July 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- 1MMGH Consulting, Zurich, Switzerland
- 2Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- 3York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, United Kingdom
- ↵*Corresponding authors: malvoltis{at}mmglobalhealth.org; paul.kaye{at}york.ac.uk
Posted July 12, 2021.
Human leishmaniasis vaccines: use cases, target population and potential global demand
